癌症
胆道癌
癌症研究
胰腺癌
结直肠癌
转移
免疫疗法
血管生成
胃肠病学
作者
Mutsunori Murahashi,Toshihisa Tsuruta,Kazunari Yamada,Yasuki Hijikata,Hisanobu Ogata,Junji Kishimoto,Sachiko Yoshimura,Tetsuro Hikichi,Yoichi Nakanishi,Kenzaburo Tani
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2021-03-01
卷期号:41 (3): 1485-1496
被引量:1
标识
DOI:10.21873/anticanres.14907
摘要
Background As the prognosis of biliary tract cancer (BTC) is extremely poor and treatment options are limited, new treatment modalities are urgently needed. We designed a phase II clinical trial to investigate the immune responses and clinical benefits of OCV-C01, an HLA-A*24:02-restricted three-peptide cancer vaccine targeting VEGFR1, VEGFR2, and KIF20A. Patients and methods Participants were patients with advanced BTC who had unresectable tumours and were refractory to standard chemotherapy. OCV-C01 was injected weekly until the discontinuance criteria were met. Results Six participants, including four patients positive for HLA-A*24:02, were enrolled in this study for assessment of efficacy. Four out of six patients exhibited vaccine-specific T-cell responses to one or more of three antigens. Log-rank tests revealed that vaccine-specific T cell responses contributed significantly to overall survival. Conclusion The cancer vaccine had positive effects on survival, indicating that this approach warrants further clinical studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI